Sarepta Therapeutics (SRPT) Posts Wider Q4 Loss; NDA Submission for Eteplirsen Planned for Mid-Year 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutic (SRPT) PT Cut to $38 at Needham & Company; 'Buy' Maintained
March 2, 2015 8:43 AM ESTNeedham & Company analyst Chad Messer cut his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $38.00 (from $52.00) but maintained a Buy rating following Q4 results and news the company remains on track to file an NDA for eteplirsen in Duchenne's muscular dystrophy (DMD) by... More
Cowen Downgrades Sarepta Therapeutic (SRPT) to Market Perform
February 27, 2015 9:15 AM ESTCowen downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Market Perform and removed its price target (prior $19.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $13.82 yesterday.
... MoreBaird Maintains Neutral View on Sarepta Therapeutic (SRPT) Post Q4
February 27, 2015 9:07 AM ESTBaird analyst Brian Skorney reiterated a Neutral rating and $16 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q4 results.
Skorney commented, "No change to outlook following 4Q14. We're remaining on the sidelines here after the 4Q14 update didn't give us enough... More
